Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | FAP | Q12884 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15327130 | 0.81 | CTSS (0.43) | CTSSALDH1A1 | |
| SCHEMBL694969 | 0.81 | CTSS (0.43) | CTSSALDH1A1 | |
| SCHEMBL15327131 | 0.81 | CTSS (0.43) | CTSSALDH1A1 | |
| SCHEMBL3798016 | 0.79 | CTSS (0.69) | CTSSKMT2AHTTAKR1C3ALDH1A1 | |
| SCHEMBL7804457 | 0.78 | CTSS (0.68) | CTSSKMT2AHTTAKR1C3 | |
| SCHEMBL18526308 | 0.76 | DPP4 (0.46) | HTTDPP4FAPHDAC2DPP8 | |
| SCHEMBL21841615 | 0.76 | DPP4 (0.46) | HTTDPP4FAPHDAC2DPP8 | |
| SCHEMBL695848 | 0.75 | CTSS (0.46) | CTSSALDH1A1HPGD | |
| SCHEMBL2683622 | 0.75 | CTSS (0.46) | CTSSALDH1A1HPGD | |
| SCHEMBL14973939 | 0.75 | CTSS (0.46) | CTSSALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524710-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524710-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2012059507-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | CTSD, CTSV, CTSS | CTSS 3/4885KMT2A 3862/4885HTT 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.